Abcalis GmbH

MULTICLONAL recombinant antibodies combine the best features of polyclonal antisera
and monoclonal antibodies while eliminating their disadvantages. By detecting more
than one epitope of the antigen, MULTICLONALS provide the sensitivity and reliability of
polyclonals, but unlike polyclonals, they do not contain any additional unknown IgG.
Accurately selected antibodies are combined in the mix, which are always defined by
their sequence. As a result, MULTICLONALS provide unlimited reproducibility and
minimized unwanted side reactivities, establishing a new quality standard for secondary
antibodies. The generation and production of MULTICLONALS is entirely animal free.

Abcalis® anti-SARS-CoV-2 antibodies are high quality recombinant monoclonal primary antibodies 
Abcalis’ product portfolio now also features anti-SARS-CoV-2 recombinant (sequence defined) monoclonal antibodies. Currently, we are offering a variety of different clones with specificities to the S1-, S1+S2-, RBD- as well as N-protein and can work with them in different projects for different applications. 
The solutions from and with Abcalis are qualified to meet regulatory standards and criteria even in the long term, as is the standard with all Abcalis products, since they are all completely sequence defined, implying their unlimited long-term availability and always identical test results. This allows for a much lower unspecific binding reactivity in many assays compared to animal based products.
Simply contact us with your specific needs or request for your setup and we will gladly explore possibilities together!

Along with our product portfolio, we also offer a variety of services around antibody development, immunoassay development, as well as antibody engineering. Through our knowledge and technology, we remain highly flexible for individual needs and specific scenarios of our customers.